Laia Rodriguez-Revenga

Dr. Laia Rodriguez-Revenga

Hospital Clinic de Barcelona, Centro de Diagonóstico Biomédico, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
AWAnne Wheeler
Anne Wheeler
DBDonald Bailey
Donald Bailey
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
JGJan Greenberg
Jan Greenberg
MLMolly Losh
Molly Losh
RHRandi Hagerman
Randi Hagerman
Changes in the fragile X mental retardation 1 gene (FMR1) have been associated with specific phenotypes, most specifically those of fragile X syndrome (FXS), fragile X tremor/ataxia syndrome (FXTAS), and fragile X primary ovarian insufficiency (FXPOI). Evidence of increased risk for additional medical, psychiatric, and cognitive features and conditions is now known to exist for individuals with a premutation, although some features have been more thoroughly studied than others. This review highlights the literature on medical, reproductive, cognitive, and psychiatric features, primarily in females, that have been suggested to be associated with changes in the FMR1 gene. Based on this review, each feature is evaluated with regard to the strength of evidence of association with the premutation. Areas of need for additional focused research and possible intervention strategies are suggested.

9 September 2017 in Fetal Diagnosis and Therapy
Verified
Journal Article
Closed access
ABAntoni Borrell
Antoni Borrell
MGMaribel Grande
Maribel Grande
MPMontse Pauta
Montse Pauta
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
FFFrancesc Figueras
Francesc Figueras
Objective: To perform a systematic review of the literature and a meta-analysis to estimate the incremental yield of chromosomal microarray analysis (CMA) over karyotyping in fetal growth restriction (FGR). Methods: This was a systematic review conducted in accordance with the PRISMA criteria. All articles identified in PubMed, Ovid Medline, and ISI Web of Knowledge (Web of Science) from January 2009 to November 2016 describing pathogenic copy number variants (CNVs) in fetuses with growth restriction were included. Case reports were excluded. Risk differences were pooled to estimate the overall and stratified CMA incremental yield. Results: Ten studies with full data available met the inclusion criteria for analysis. Combined data from these studies revealed a 4% (95% confidence interval [CI] 1-6%) incremental yield of CMA over karyotyping in nonmalformed growth-restricted fetuses, and a 10% (95% CI 6-14%) incremental yield in FGR when associated with fetal malformations. The most frequently found pathogenic CNVs were 22q11.2 duplication, Xp22.3 deletion, and 7q11.23 deletion (Williams-Beuren syndrome), particularly in isolated FGR. Conclusion: The use of genomic CMA provides a 4% incremental yield of detecting pathogenic CNVs in fetuses with isolated growth restriction and normal karyotype.

29 November 2007 in BMC Genomics
Verified
Journal Article
Open access
PDF file
IMIrene Madrigal
Irene Madrigal
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
LAL Armengol
L Armengol
EGEva González-Roca
Eva González-Roca
BRB Rodriguez
B Rodriguez
MMM Milà
M Milà
Background: Aproximately 5–10% of cases of mental retardation in males are due to copy number variations (CNV) on the X chromosome. Novel technologies, such as array comparative genomic hybridization (aCGH), may help to uncover cryptic rearrangements in X-linked mental retardation (XLMR) patients. We have constructed an X-chromosome tiling path array using bacterial artificial chromosomes (BACs) and validated it using samples with cytogenetically defined copy number changes. We have studied 54 patients with idiopathic mental retardation and 20 controls subjects. Results: Known genomic aberrations were reliably detected on the array and eight novel submicroscopic imbalances, likely causative for the mental retardation (MR) phenotype, were detected. Putatively pathogenic rearrangements included three deletions and five duplications (ranging between 82 kb to one Mb), all but two affecting genes previously known to be responsible for XLMR. Additionally, we describe different CNV regions with significant different frequencies in XLMR and control subjects (44% vs. 20%). Conclusion: This tiling path array of the human X chromosome has proven successful for the detection and characterization of known rearrangements and novel CNVs in XLMR patients.

1 February 2016 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
RCRosa Calvo-Escalona
Rosa Calvo-Escalona
ONOlga Puig Navarro
Olga Puig Navarro
IMIrene Madrigal
Irene Madrigal
IQInes Quintela
Ines Quintela
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga

12 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
JCJordi Corominas
Jordi Corominas
CGChristian Gilissen
Christian Gilissen
ASAurora Sanchez
Aurora Sanchez
IMIrene Madrigal
Irene Madrigal
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
Advances in high-throughput technologies and its implementation worldwide have had a considerable impact on the elucidation of the molecular causes underlying neurodevelopmental psychiatric disorders, especially for autism spectrum disorder and intellectual disability (ID). Nevertheless, etiology remains elusive in close to 50% of cases, even in those families with multiple affected individuals, strongly hinting at a genetic cause. Here we present a case report of two siblings affected with severe ID and other comorbidities, who embarked on a genetic testing odyssey until diagnosis was reached by using whole genome sequencing (WGS). WGS identified a maternally inherited novel missense variant (NM_031466.7:c.1037G > A; p.Gly346Glu) and a paternally inherited 90 kb intragenic deletion in TRAPPC9 gene. This report demonstrates the clinical utility of WGS in patients who remain undiagnosed after whole exome sequencing.

6 July 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
IMIrene Madrigal
Irene Madrigal
ABAntoni Borrell
Antoni Borrell
JMJosep M. Martinez
Josep M. Martinez
JSJoan Sabria
Joan Sabria
MMMontserrat Milà
Montserrat Milà